Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial

Core Viewpoint - The drugmaker presents strong evidence that fenebrutinib could be the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis [1] Group 1 - Fenebrutinib is positioned as a potential breakthrough in the treatment of multiple sclerosis [1] - The results indicate a significant advancement in oral treatment options for patients with relapsing and primary progressive forms of the disease [1]